Butler Hospital will renovate its 120-year-old Weld Building to house a major expansion of the Memory and Aging program. Once completed, the program will expand into 18,000 square feet on three floors to accommodate screenings, therapy infusions, cognitive assessments, and consultations.
The renovation will support Butler’s involvement in an impressive range of trials of new treatments and the development of new diagnostic tools, prevention programs, and awareness programs that help dispel the fear and stigma surrounding Alzheimer’s disease. These programs feature dynamic collaborations with the Alpert Medical School and researchers at hospitals and universities across Rhode Island and the nation.
To achieve our vision and goals on behalf of the patients we serve, we will need your help and support. To that end, Butler Hospital, an affiliate of Care New England, will launch a fundraising effort through which we will endeavor to raise as much of the $3 million cost of this essential and extraordinary initiative as possible. Unequivocally, the ultimate success of this philanthropic effort will depend upon your generous philanthropic investment.
- Stephen Salloway, MD, MS
Professor of Neurology and Psychiatry, Alpert Medical School, and Director, Memory & Aging Program
Currently, we are collaborating with researchers at the Alpert Medical School and Miriam Hospital to conduct a clinical trial on the treatment of Alzheimer’s disease with the drug Emtriva. This trial will be the first of its kind to use this class of drug to reduce inflammation due to cellular aging in the context of Alzheimer’s.
Butler has been active in phase-three clinical trials of Aduhelm, which targets the build-up of amyloid in the brain, long suspected as a cause of Alzheimer’s. A significant expansion of the Weld Building and our infusion capacity will greatly help to address the anticipated high demand for this very hopeful treatment.
Butler is collaborating with researchers at the University of Rhode Island and BayCare Health System in Florida to launch a clinical trial of retinal screening processes that could help clinicians detect Alzheimer’s disease as much as two or more decades before patients develop life-changing symptoms.
Your donation will go directly to our Weld Build Renovation